1. Preoperative evolocumab combined with rosuvastatin did not significantly reduce six-month major adverse cardiovascular events but improved several clinically relevant ...
1. The exercise training prevented increases in total cholesterol and LDL cholesterol which were observed in the non-exercise group and ...
1. Patients who received statin therapy using a treat-to-target approach (targeting LDL-cholesterol of 50-70mg/dL) did not have worse cardiovascular outcomes ...
![Ivabradine ineffective in stable coronary artery disease [SIGNIFY trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/09/800px-RCA_atherosclerosis-350x250.jpg)
1. Olpasiran significantly and substantially reduced lipoprotein(a) concentration in patients with atherosclerotic cardiovascular disease compared to placebo. 2. Olpasiran reduced ...
1. A significantly greater proportion of patients receiving 2-3 lipid lowering medications achieved LDL-cholesterol targets compared to those receiving monotherapy. ...
1. In this study, improved sleep quality was associated with significantly decreased systolic blood pressure and increased high-density lipoprotein levels ...
1. In individuals aged 70-100 years, there was a significantly increased risk of myocardial infarction and atherosclerotic cardiovascular disease for ...
1. In patients aged ≥75 years, LDL cholesterol-lowering therapies reduced the risk for major vascular events, including cardiovascular death, myocardial ...
1. Evinacumab significantly lowered low-density lipoprotein (LDL) cholesterol levels in patients with homozygous familial hypercholesterolemia. 2. Patients receiving evinacumab did ...
1. Evinacumab significantly lowered low-density lipoprotein (LDL) cholesterol levels in patients with homozygous familial hypercholesterolemia. 2. Patients receiving evinacumab did ...
